Osteoporosis & Bone Metabolism Disorders 2008-2023

Osteoporosis & Bone Metabolism Disorders 2008-2023

In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured?

The majority of this market consists of the fast-expanding osteoporosis segment, a disease with high incidence and under-treatment at present. The bone metabolism market is competitive and progressive, facing generic competition amongst its top-selling drugs. Nevertheless, market growth will be driven by aging populations worldwide and the entry of novel therapies during the years ahead. In Osteoporosis & Bone Metabolism Disorders, 2008-2023, visiongain forecasts that the bone metabolism disorder market will increase - but by just how much? Order the report today to find out..

Worldwide, significant numbers of osteoporosis sufferers remain undiagnosed. Amongst those taking medication, patient compliance is poor. In addition, bone metabolism disease patients have significant unmet needs. All these factors provide additional opportunities for further growth in the market. During this growth period, there will be major changes in the nature and make-up of the bone metabolism disorder market. This will include the decline in bisphosphonate drugs and the emergence of novel therapies.

This visiongain report reviews the global bone metabolism disorder market in detail thorough comprehensive forecasting and other analysis, as well as interviews with experts in the field, including KOLs in industry. In particular, Osteoporosis & Bone Metabolism Disorders, 2008-2023 concentrates on the following essential aspects of the global osteoporosis and bone metabolism market:

• Financial forecasts covering the period 2008-2023, including leading brands, companies, country markets and therapeutic classes of drug
  
  
• Expert opinion from industry sources
  
  
• Identification of key drugs in a well-stocked bone metabolism disorder pipeline
  
  
• Key industrial players - established and emerging - in the bone metabolism market
  
  
• Geographical breakdown of the market, including sales forecasts for leading markets, including China and India

• To receive a comprehensive analysis of the prospects for the osteoporosis and bone metabolism industry from 2008-2023, including sales forecasts, major growth areas and most talked-about pipeline products
  
  
• To discover predicted revenues, growth rates and other key metrics for bone disorder drugs from 2008-2023, especially leading brands

• Drivers and restraints on market
  
  
• Competition
  
  
• Strengths, weaknesses, opportunities and threats.
  
  
• To find out where the bone metabolism market is heading from 2008 onwards - both technologically and commercially

1 Executive Summary

2 Bone Metabolism Disorders: Causes, Diagnosis and Treatment

2.1 Bone is a Living Dynamic Tissue

2.1.1 Bone Structure

2.1.2 Bone Remodelling

2.1.3 Regulation of Bone Remodelling

2.1.3.1 Factors Affecting Bone Metabolism

2.1.3.2 Parathyroid Hormone (PTH)

2.1.3.3 Calcitonin

2.1.3.4 Vitamin D/Calcitriol

2.1.3.5 Other Hormones

2.1.3.6 Local Cell Signalling Factors

2.1.3.7 Physical Stress

2.1.4 Bone Growth and Remodelling During the Life-Cycle

2.2 Bone Metabolism Disorders

2.2.1 Osteoporosis

2.2.1.1 Osteoporosis Leads to Bone Fractures

2.2.1.2 Causes of Osteoporosis

2.2.1.3 Osteoporosis Risk Factors

2.2.1.4 Diagnosis of Osteoporosis

2.2.1.5 Osteoporosis Screening

2.2.1.6 Prevalence of Osteoporosis

2.2.1.7 Counting the Cost of Osteoporosis

2.2.2 Paget's Disease of Bone

2.2.2.1 Paget's Disease is a Chronic Skeletal Disorder

2.2.2.2 The Cause of Paget's Disease

2.2.2.3 Diagnosis of Paget's Disease

2.2.2.4 Prevalence of Paget's Disease

2.2.3 Bone Metastases

2.2.4 Primary Hyperparathyroidism

2.2.5 Secondary Hyperparathyroidism and Renal Osteodystrophy

2.3 Treatment of Bone Metabolism Disorders

2.3.1 Bisphosphonates

2.3.2 Vitamin D and K Analogues/Calcimimetics

2.3.3 Selective Oestrogen-Receptor Modulators (SERMs)

2.3.4 Parathyroid Hormones (PTH)

2.3.5 Calcitonins

2.3.6 Strontium Compounds

2.3.7 Hormone Replacement Therapy (HRT)

2.3.8 Calcium and Vitamin D Supplements

3 The World Bone Metabolism Disorder Market

3.1 The Bone Metabolism Market Will Grow 2023

3.2 Osteoporosis Dominates the Bone Metabolism Market

3.3 Bisphosphonates Lead the Bone Metabolism Market in 2007

3.4 Bisphosphonates Will Gradually Lose Market Share during 2008-2023

3.5 Key Industrial Players in the Bone Metabolism Market

3.6 Leading Brands in the Bone Metabolism Market

3.6.1 The Top 14 Bone Metabolism Drugs in 2007

3.6.2 Fosamax: A Fall from Top Position in 2008

3.6.3 Actonel/Optinate: Increasingly Impacted by Generic Competition

3.6.4 Zometa/Aclasta/Reclast (Zoledronate, Novartis): Further Growth Predicted

3.6.5 Bonviva/Boniva/Bondronat (Ibandronate, Roche/GSK): Strong Growth in Near Term

3.6.6 Bonalon/Teiroc (Alendronate, Teijin)

3.6.7 Benet (Risedronate, Takeda)

3.6.8 Bonefos (Clodronate, Bayer)

3.6.9 Generic Alendronate

3.6.10 Zemplar: New Formulations and Indications

3.6.11 Sensipar/Mimpara: Amgen's Calcimimetic

3.6.12 Alfarol (Alfacalcidol, Chugai)

3.6.13 Rocaltrol (Calcitriol, Roche)

3.6.14 Glakay (Vitamin K2, Eisai)

3.6.15 Evista: Only Slight Growth Predicted

3.6.16 Forteo/Forsteo: Strong Growth for a Bone Anabolic Agent

3.6.17 Preotact Will Not Challenge Forteo

3.6.18 Miacalcin/Miacalcic (Salmon Calcitonin, Novartis)

3.6.19 Elcitonin (Eel Calcitonin Derivative, Asahi Kasei)

3.6.20 Fortical (Salmon Calcitonin, Upsher-Smith)

3.6.21 Protelos (Strontium Ranelate, Servier)

3.6.22 Hormone Replacement Therapy (HRT)

3.6.23 The Leading Calcium and Vitamin D Supplements

4 SWOT Analysis of the Bone Metabolism Disorder Market

4.1 Analysis of the Market

4.2 Key Strengths of the Bone Metabolism Pharmaceutical Industry

4.3 Generic Competition is the Key Weakness Facing the Bone Metabolism Pharmaceutical Industry

4.4 Key Opportunities for the Bone Metabolism Market

4.5 Key Threats to the Bone Metabolism Market

4.5.1 Drug Side-Effect Publicity

4.5.2 Reimbursement of Bone Metabolism Drugs

5 Geographical Profile of the Bone Metabolism Market

5.1 North America Lead the Bone Metabolism Market in 2007

5.2 Leading Bone Metabolism Country Markets, 2007

5.3 Bone Metabolism Market Forecast for Leading Countries, 2008-2023

5.4 China and India Will Have Highest Growth in 2008-2023

6 The Bone Metabolism Disorder Pipeline

6.1 The Bone Metabolism Pipeline is Well-Stocked

6.2 More Convenient Formulations and Novel Therapeutics Fill the Bone Metabolism Pipeline

6.2.1 Pipeline Developments to Improve Formulations

6.2.2 Pipeline Bone Anabolic Agents

6.3 Monoclonal Antibodies and Cathepsin K Inhibitors will be the First Novel Therapeutics to Reach Market

6.4 Key Pipeline Products: Registration Stage

6.4.1 Fablyn (Lasofoxifene, Pfizer/Ligand)

6.4.2 Viviant (Bazedoxifene, Wyeth)

6.5 Key Pipeline Products: Phase III

6.5.1 Denosumab/AMG 162 (Amgen)

6.5.1.1 Denosumab is a Pipeline Product for Osteoporosis and Bone Metastases

6.5.1.2 Osteoporosis Clinical Trials

6.5.1.3 Bone Metastases Clinical Trials

6.5.1.4 Launch of Denosumab Expected in 2009-2010

6.5.2 Odanacatib (MK 0822, Merck & Co.)

6.5.3 Aprela (Conjugated Oestrogenic Substances/Bazedoxifene, Wyeth)

6.5.4 Arzoxifene (Eli Lilly)

6.5.5 Recalbon (ONO-5920/YM529, Minodronate, Ono/Astellas)

6.5.6 ED-71 (Eldecalcitol Chugai)

6.5.7 SMC021 (Salmon Calcitonin, Novartis/Nordic Bioscience/Unigene/Emisphere)

6.6 Key Pipeline Products: Phase II

6.6.1 ACE-011 (Acceleron Pharma)

6.6.2 BA058 (PTHrP Analogue, Radius Health/Ipsen)

6.6.3 Ronacaleret/751689 (GSK/NPS)

6.6.4 ONO-5334 (Ono)

6.6.5 rhPTH (Recombinant Human PTH, Green Cross)

6.6.6 BN003/CaPTHymone (Oral PTH, Bone Medical/Axcess)

6.6.7 ViaDerm-hPTH (PTH, TransPharma/Eli Lilly)

6.6.8 NBS-101 (Strontium Malonate, Osteologix)

6.6.9 Capsitonin (Oral Calcitonin, Bone Medical)

7 Conclusions

Appendix A

About visiongain

Appendix B

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Hormones Involved in Bone Metabolism

Table 2.2 Worldwide Prevalence of Osteoporosis

Table 2.3 Bone Metabolism Disease Therapies

Table 3.1 World Bone Metabolism Disorder Pharmaceutical Sales ($m) 2007-2023

Table 3.2 World Bone Metabolism Market Share by Disorder, 2007

Table 3.3 World Bone Metabolism Market Share by Drug Class, 2007

Table 3.4 World Bone Metabolism Disorder Sales ($m) by Drug Class, 2007-2023

Table 3.5 World Bone Metabolism Disorder Market Share by Manufacturer, 2007

Table 3.6 Leading Bone Metabolism Disorder Brands, 2007

Table 3.7 Leading Bone Metabolism Disorder Brand Sales ($m), 2007- 2023

Table 3.8 Key Generic Alendronate Manufacturers, 2007

Table 3.9 Largest-Selling HRT Products, 2007

Table 4.1 SWOT Chart for Bone Metabolism Disorder Market

Table 4.2 Selected Expected Patent-Expiries in the Bone Metabolism Market 2008-2023

Table 4.3 Premarin Sales Revenue 2002-2004

Table 5.1 World Bone Metabolism Disorder Market Share by Geographical Area, 2007

Table 5.2 Top Bone Metabolism Country Markets, 2007

Table 5.3 Leading Bone Metabolism Country Markets, 2007-2023

Table 5.4 Population Aged 65 or Over: US, Japan China and India, 2007-2023

Table 6.1 The Bone Metabolism Disorder Pipeline

Table 7.1 Leading Bone Metabolism Country Markets 2007 and 2023  

List of Figures

Figure 2.1 Appearance of Healthy Bone

Figure 2.2 Bone Affected by Osteoporosis

Figure 2.3 Bones Commonly Affected by Paget's Disease

Figure 3.1 World Bone Metabolism Disorder Pharmaceutical Sales ($m) 2007-2023

Figure 3.2 World Bone Metabolism Market Share by Disorder, 2007

Figure 3.3 World Bone Metabolism Disorder Market Share by Drug Class, 2007

Figure 3.4 World Bone Metabolism Disorder Sales ($m) by Drug Class, 2007-2023

Figure 3.5 World Bone Metabolism Disorder Market Share by Drug Class, 2013

Figure 3.6 World Bone Metabolism Disorder Market Share by Drug Class, 2018

Figure 3.7 World Bone Metabolism Disorder Market Share by Drug Class, 2023

Figure 3.8 World Bone Metabolism Disorder Market Share by Manufacturer, 2007

Figure 3.9 Leading Bone Metabolism Disorder Brands, 2007

Figure 3.10 Leading Bone Metabolism Brand Sales ($m) (Bisphosphonates), 2007-2023

Figure 3.11 Leading Bone Metabolism Brand Sales (Non-Bisphosphonates), 2007-2023

Figure 3.12 Fosamax/Fosamax Plus D Worldwide Sales Forecast ($m), 2007-2023

Figure 3.13 Actonel/Optinate Worldwide Sales Forecast ($m), 2007-2023

Figure 3.14 Zometa/Aclasta/Reclast Worldwide Sales Forecast ($m), 2007-2023

Figure 3.15 Bonviva/Boniva/Bondronat Worldwide Sales Forecast ($m), 2007-2023

Figure 3.16 Zemplar Worldwide Sales Forecast ($m), 2007-2023

Figure 3.17 Sensipar/Mimpara Worldwide Sales Forecast ($m), 2007- 2023

Figure 3.18 Evista Worldwide Sales Forecast ($m), 2007-2023

Figure 3.19 Forteo/Forsteo Worldwide Sales Forecast ($m), 2007-2023

Figure 3.20 Miacalcin/Miacalcic Worldwide Sales Forecast ($m), 2007- 2023

Figure 3.21 Protelos Worldwide Sales Forecast ($m), 2007-2023

Figure 5.1 World Bone Metabolism Disorder Market Share by Geographical Area, 2007

Figure 5.2 World Bone Metabolism Disorder Market Share by Leading Countries, 2007

Figure 5.3 Leading Bone Metabolism Country Markets, 2007-2023: Higher Group

Figure 5.4 Leading Bone Metabolism Country Markets, 2007-2023: Lower Group

Figure 5.5 World Bone Metabolism Disorder Market Share by Leading Countries, 2013

Figure 5.6 World Bone Metabolism Disorder Market Share by Leading Countries, 2018

Figure 5.7 World Bone Metabolism Disorder Market Share by Leading Countries, 2023

Figure 7.1 Bone Metabolism Disorder Market, 2007-2023

Companies Listed

Abbott Laboratories

Abiogen

Acceleron Pharma

American College of Physicians

Amgen

Asahi Kasei

Astellas

Axcess

Banyu

Barr

Bayer

Bone Medical

British Geriatrics Society

British Orthopaedic Association

Celgene

Chugai (part of Roche Group)

Daiichi Sankyo

Dr.Reddy's

Eisai

Eli Lilly

Emisphere Technologies

Esteve

European Medicines Agency (EMEA)

Food and Drug Administration (FDA)

Green Cross

GlaxoSmithKline (GSK)

International Osteoporosis Foundation

Ipsen

Kirin Brewery

Leo Pharma

Ligand

Merck & Co.

Nordic Bioscience

Novartis

Novo Nordisk

NPS

Nycomed

Ono

Osteologix

Preventive Services Task Force (USPSTF)

Proctor & Gamble

Radius Health

Ratiopharm

Roche

Sandoz (Novartis)

Sanofi-Aventis

Servier

Shire

Sigma (Australia)

Stada

Taisho

Takeda

Teijin

Teva

TransPharma

Unigene

Upsher-Smith

Watson

World Health Organisation (WHO)

Wyeth